Abstract:Objective: Overexpression of human epidermal growth factor receptor-2 (HER2) in breast cancers provides promising opportunities for imaging and targeted therapy. Developing HER2 targeted positron emission tomography (PET) probes might be benefit for management of the disease. Small high-affinity scaffold proteins, affibodies, are ideal vectors for imaging HER2 overexpressed tumors. Despite of the initial success on development of 18F labeled ZHER2:342 affibody, the tedious synthesis producers, low yields and unfavorable pharmacokinetics may hinder the clinical use. 68Ga is an attractive positron emitter for PET imaging. A simple preparation of 68Ga labeled ZHER2:342 analog, 68Ga-NOTA-MAL-Cys-MZHER2:342, was reported in the study. The in vivo performances of the tracer for assessing HER2 status in breast cancers were also evaluated. Methods: NOTA-MAL conjugated Cys-MZHER2:342 was radiolabeled with 68Ga. The probe was evaluated by in vitro tests including stability and cell binding studies in breast cancer cells with different HER2 levels. In vivo evaluation was performed in mice bearing tumors using microPET imaging and biodistribution experiments. A PET/CT imaging study was initially performed in patients with breast cancers. Results: The tracer was synthesized in a straightforward chelation method with satisfactory non-decay corrected yield (81±5%) and radiochemical purity (>95%). In vivo micro-PET imaging showed that HER2 high levels expressed BT474 xenografts were more clear visualized than HER2 low levels expressed MCF-7 tumors (16.12 ± 2.69 ID%/g vs 1.32 ± 0.19 ID%/g at 1 h post-injection). The outcome was consistent with the immunohistochemical analysis. No significant radioactivity was accumulated in healthy tissues (less than 2% ID/g) except kidneys. In a preliminary clinical study, 68Ga-NOTA-MAL-Cys-MZHER2:342 PET imaging allowed more high-contrast detection of HER2 positive primary tumors (maximum standardized uptake value = 2.16±0.27) than those in HER2 negative primary focus (maximum standardized uptake value = 0.32±0.05). No detectable side-effects were found. Conclusion: In summary, this study indicates the significant efficiency of the 68Ga labeled HER2 affibody. Preclinical and clinical studies support the possibility of monitoring HER2 levels in breast cancers using 68Ga-NOTA-MAL-Cys-MZHER2:342. Advances in knowledge: The research investigated the feasibility of a 68Ga labeled HER2 affibody modified with a hydrophilic linker for breast cancer PET imaging. Favorable outcomes showed that the probe might be valuable for determining HER2 status of the disease.

Development and Biological Evaluation of 68Ga-Labeled Peptides for Potential Application in HER2-positive Colorectal Cancer

<SUP>68</SUP>Ga-Labeled GX1 Dimer: A Novel Probe for PET/Cerenkov Imaging Targeting Gastric Cancer

188Re-Labeled GX1 Dimer As a Novel Dual-Functional Probe Targeting TGM2 for Imaging and Antiangiogenic Therapy of Gastric Cancer

PET imaging of a 68Ga labeled modified HER2 affibody in breast cancers: from xenografts to patients

Transfer of gentamicin resistance between cultures of Staphylococcus aureus in nutrient broth, serum and urine.

Cetylpyridinium chloride at the mica-water interface: incomplete monolayer and bilayer structures.

Tracing Investigation of Targeting Gastric Cancer with 18F Labeled Anti-Human Epidermal Growth Factor Receptor 2 Specific Affibody Molecule ZHER2:342

Targeting HER2-positive Gastric Cancer with a Novel 18F-Labeled ZHER2:342 Probe

[Left atrial rhythm: 5 cases in children].

Radiolabeling and Evaluation of (64)Cu-Dota-f56 Peptide Targeting Vascular Endothelial Growth Factor Receptor 1 in the Molecular Imaging of Gastric Cancer.

CMKLR1-targeting peptide tracers for PET/MR imaging of breast cancer

Interpretation of nucleic acid synthesis. Studies in renal-failure lymphocytes.

Developing PEGylated Reversed D-Peptide As a Novel HER2-Targeted SPECT Imaging Probe for Breast Cancer Detection

Synthesis and Evaluation of Novel 68Ga-Labeled [D-Phe6,Leu13ψThz14]bombesin(6-14) Analogs for Cancer Imaging with Positron Emission Tomography

Evaluation of 68Ga- and 177Lu-Labeled HZ20 Angiotensin-Converting Enzyme 2-Targeting Peptides for Tumor-Specific Imaging.

Molecular Insights into Vesicle Tethering at the Golgi by the Conserved Oligomeric Golgi (COG) Complex and the Golgin TATA Element Modulatory Factor (TMF)*

A Preliminary Study of a 68Ga-Labeled PET Probe for HER2 Imaging

Construction of 124 I-trastuzumab for noninvasive PET imaging of HER2 expression: from patient-derived xenograft models to gastric cancer patients

Noninvasive Detection of HER2 Expression in Gastric Cancer by 64Cu-Nota-trastuzumab in PDX Mouse Model and in Patients

Synthesis and evaluation of 64 Cu-radiolabeled NOTA-cetuximab ( 64 Cu-NOTA-C225) for immuno-PET imaging of EGFR expression.

Effects of 68Ga-labeled PEG and non-PEG variant peptides as HER2-targeting probes on the progression of gastrointestinal (GI) tumor cells